The vaccine goal

in page functions

Accelerate the uptake and use of underused and new vaccines by strengthening country decision-making and introduction

Vaccine goal

The first 10 years of Gavi's work focused mainly on catalysing adoption of vaccines against yellow fever, hepatitis B (hepB) and Haemophilus influenzae type b (Hib).
 

In the next decade, Gavi will maintain momentum on these antigens but also target new vaccines, which hold the greatest potential to achieve progress on the Millennium Development Goals (MDG), in particular MDG 4 - the reduction of child mortality.

100 new vaccine introductions

Gavi's ambition is to accelerate the introduction of routine meningitis, pneumococcal and rotavirus vaccines and support campaigns against yellow fever and meningitis.

Goal-level indicators

Strategic objectives

 

The Vaccine Alliance will also begin activities to prepare for other new vaccines, including human papillomavirus (HPV), Japanese encephalitis, typhoid and rubella.

If the Vaccine Alliance is fully resourced to meet demand, up to 100 new vaccine introductions across Gavi-eligible countries would occur during the second five-year strategy. The majority of these introductions are pneumococcal and rotavirus vaccines.

Rwanda's pneumococcal vaccine roll-out, one year on

12 months after Rwanda became the first African country to introduce pneumococcal vaccine, UNICEF visit Nyamata health centre to check on progress in the fight against the continent’s number one child killer.

Read more

Rwanda health clinic 2010 - injection

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

More facts...

close icon

modal window here